|
Characteristic
|
Overall (N = 75)
|
Infliximab + CS (N = 36)
|
CS Alone (N = 39)
|
P Value
|
|---|
|
Median Age (Interquartile Range)
| |
63 years (50–71 years)
|
61 years (52–72 years)
|
0.633
|
|
Sex, No. (%)
|
|
Male
|
50 (66.7)
|
29 (80.6)
|
21 (53.8)
|
0.016
|
|
Female
|
25 (33.3)
|
7 (19.4)
|
18 (46.2)
|
0.016
|
|
Cancer Type, No. (%)
|
|
Melanoma
|
53 (70.7)
|
29 (80.6)
|
24 (61.5)
|
0.167
|
|
Genitourinarya
|
15 (20.0)
|
7 (19.4)
|
8 (20.5)
| |
|
Head and Neck Cancer
|
1 (1.3)
|
0
|
1 (2.6)
| |
|
Leukemia
|
1 (1.3)
|
0
|
1 (2.6)
| |
|
Lung Cancer
|
2 (2.7)
|
0
|
2 (5.1)
| |
|
Otherb
|
3 (4.0)
|
0
|
3 (7.7)
| |
|
Immunotherapy Type, No. (%)
|
|
Ipilimumab
|
45 (60.0)
|
21 (58.3)
|
24 (61.5)
|
0.834
|
|
Ipilimumab + Nivolumab
|
12 (16.0)
|
6 (16.7)
|
6 (15.4)
| |
|
Nivolumab
|
4 (5.3)
|
1 (2.8)
|
3 (7.7)
| |
|
Pembrolizumab
|
13 (17.3)
|
7 (19.4)
|
6 (15.4)
| |
|
Tremelimumab
|
1 (1.3)
|
1 (2.8)
|
0
| |
|
Symptoms at Onset, No. (%)
|
|
Diarrhea
|
73 (97.3)
|
36 (100)
|
37 (94.9)
|
0.494
|
|
Nausea
|
21 (28.0)
|
8 (22.2)
|
13 (33.3)
|
0.315
|
|
Vomiting
|
11 (14.7)
|
3 (8.3)
|
8 (20.5)
|
0.195
|
|
Abdominal Cramps
|
32 (42.7)
|
13 (36.1)
|
19 (48.7)
|
0.351
|
|
Blood in Stool
|
22 (29.3)
|
14 (38.9)
|
8 (20.5)
|
0.127
|
|
Mucus in Stool
|
2 (2.7)
|
0
|
2 (5.1)
|
0.494
|
|
Elevated WBC Counts
|
3 (4.0)
|
1 (2.8)
|
2 (5.1)
|
1
|
|
Pathology, No. (%)
|
|
Positive
|
37 (49.3)
|
20 (55.6)
|
17 (43.6)
|
0.534
|
|
Negative
|
6 (8.0)
|
2 (5.6)
|
4 (10.3)
| |
|
Not Tested
|
32 (42.7)
|
14 (38.9)
|
18 (46.2)
| |
- aIncludes renal cell carcinoma, urothelial carcinoma, and prostate cancer
- bIncludes anal squamous cell cancer, pancreatic cancer, and glioblastoma
- CS corticosteroids, WBC White blood cells
